PRMT1 mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes cholangiocarcinoma progression

Key Points

• The main aim is to explore the role of DDX1-R602-ADMA modification in cholangiocarcinoma progression.
• Identified the DDX1-R602-ADMA modification in cholangiocarcinoma samples.
• Examined the influence of ADMA modification on DDX1 function.
• Investigated the USP10-PRMT1-DDX1 signaling axis.
• DDX1-R602-ADMA modification is confirmed as crucial for cholangiocarcinoma progression.
• Targeting the USP10-PRMT1-DDX1 axis shows potential as a therapeutic strategy.